Innovent Biologics up 10%
Innovent Biologics rises on Pfizer collaboration deal worth up to $10.5 billion to develop oncology medicines. Partnership aims to develop new cancer treatments.
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.